BioLife Solutions and BroadOak Capital Partners led a founding round in Pluristyx.

BioLife Solutions and BroadOak Capital Partners, life sciences focused venture capital firms, led a founding round in Pluristyx, a provider of induced pluripotent stem cell technologies and proprietary gene editing solutions. Financial terms were not disclosed. "We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment. The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges,” Benjamin Fryer, Pluristyx CEO.